Literature DB >> 16352489

Leukocyte depleting filter attenuates myocardial injury during elective coronary artery bypass surgery.

Juha Koskenkari1, Jussi Rimpiläinen, Fausto Biancari, Heljä-Marja Surcel, Päivi Kaukoranta, Kai Kiviluoma, Tero Ala-Kokko, Tatu Juvonen.   

Abstract

BACKGROUND: Ischemia-reperfusion injury secondary to leukocyte activation has been widely recognized as one of the most relevant mechanism leading to postoperative organ dysfunction occurring after a period of ischemia. The aim of the present study was to evaluate in a prospective, randomized study, the value of leukocyte depleting filter in patients undergoing elective coronary artery bypass surgery.
METHODS: Twenty patients scheduled for elective on-pump coronary artery bypass surgery were randomized to undergo cardiopulmonary bypass either with a leukocyte depleting filter incorporated in the extracorporeal circulation arterial line or without a filter.
RESULTS: The main finding of this study was the significantly lower postoperative concentrations of cardiac troponin I in the leukocyte filter group (Tests of between-subjects effects: p = 0.024). There were also slightly better cardiac indices in the leukocyte filter group. A larger amount of blood units was infused intra- and postoperatively in patients undergoing cardiopulmonary bypass with leukocyte filtration (median, 600 [IQR, 0-1200] vs. 0 [IQR, 0-600], p = 0.08). Two patients in the leukocyte filter group underwent reoperation for bleeding but none in the control group (p = 0.48). Intra-and postoperative platelet count was lower in the leukocyte filter group (Tests of between-subjects effects: p = 0.08). Despite a significant increased concentration of C-reactive protein on the first postoperative day in the control group (p = 0.029), repeated-measures analysis failed to show any significant increase during the study period (p = 0.33).
CONCLUSIONS: The results of this study suggest a myocardial protective effect of leukocyte filter in the setting of elective coronary artery bypass surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352489     DOI: 10.1080/14017430510035943

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  3 in total

Review 1.  Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.

Authors:  Aslan T Turer; Joseph A Hill
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 2.  Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion.

Authors:  Daniel Simancas-Racines; Dimelza Osorio; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2015-12-03

3.  Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study.

Authors:  Wei Zhou; Tao Wang; Ling-Juan Zhu; Ming-Hua Wen; Li-Hua Hu; Xiao Huang; Chun-Jiao You; Ju-Xiang Li; Yan-Qing Wu; Qing-Hua Wu; Hui-Hui Bao; Xiao-Shu Cheng
Journal:  Chin Med J (Engl)       Date:  2019-09-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.